Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Company Overview - Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, particularly in areas of high unmet medical need [4] - The company's lead clinical program is pociredir, designed to increase fetal hemoglobin expression for the treatment of sickle cell disease (SCD) [4] Clinical Development - Fulcrum will present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease on February 24, 2026 [1] - Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED), leading to downregulation of fetal globin repressors and increased fetal hemoglobin [5] - In the PIONEER trial, pociredir has shown dose-dependent increases in fetal hemoglobin, improvements in markers of hemolysis and anemia, and has been generally well-tolerated with no serious adverse events reported [5] Expert Involvement - Dr. Martin Steinberg, a prominent hematologist with extensive research on sickle cell disease, will join Fulcrum management for the conference call [2][3] - Dr. Steinberg has published over 450 articles and has contributed significantly to understanding the genetic basis and pathophysiology of sickle cell disease [3] Regulatory Status - Pociredir has received Fast Track and Orphan Drug Designation from the FDA for the treatment of sickle cell disease [5] Disease Background - Sickle cell disease is a genetic disorder caused by a mutation in the HBB gene, leading to inefficient oxygen transport and sickle-shaped red blood cells, which can cause various serious health complications [6]